Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor
Temozolomide or dacarbazine-based chemotherapy combined with endostatin have efficacy in well-differentiated pancreatic neuroendocrine tumor
Advanced Well-differentiated Pancreatic Neuroendocrine Tumor
DRUG: temozolomide or dacarbazine-based chemotherapy, endostatin
overall response rate, up to 12 months
progression free survival, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months|toxicities, Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Temozolomide or dacarbazine-based chemotherapy combined with endostatin have efficacy in well-differentiated pancreatic neuroendocrine tumor